Navigation Links
Study brings greater understanding of tumor growth mechanism
Date:5/16/2013

A study led by researchers from Plymouth University Peninsula Schools of Medicine and Dentistry has for the first time revealed how the loss of a particular tumour suppressing protein leads to the abnormal growth of tumours of the brain and nervous system.

The study is published in Brain: A Journal of Neurology.

Tumour suppressors exist in cells to prevent abnormal cell division in our bodies. The loss of a tumour suppressor called Merlin leads to tumours in many cell types within our nervous systems. There are two copies of a tumour suppressor, one on each chromosome that we inherit from our parents. The loss of Merlin can be caused by random loss of both copies in a single cell, causing sporadic tumours, or by inheriting one abnormal copy and losing the second copy throughout our lifetime as is seen in the inherited condition of neurofibromatosis type 2 (NF2).

With either sporadic loss or inherited NF2, these tumours lacking the Merlin protein develop in the Schwann cells that form the sheaths that surround and electrically insulate neurons. These tumours are called schwannomas, but tumours can also arise in the cells that form the membrane around the brain and spinal cord, and the cells that line the ventricles of the brain.

Although the schwannomas are slow-growing and benign, they are frequent and come in numbers. The sheer number of tumours caused by this gene defect can overwhelm a patient, often leading to hearing loss, disability and eventually death. Patients can suffer from 20 to 30 tumours at any one time, and the condition typically manifests in the teenage years and through into adulthood.

No effective therapy for these tumours exists, other than repeated invasive surgery or radiotherapy aiming at a single tumour at a time and which is unlikely to eradicate the full extent of the tumours.

The Brain study investigated how loss of a protein called Sox10 functions in causing these tumours. Sox10 is known to play a major role in the development of Schwann cells, but this is the first time it has been shown to be involved in the growth of schwannoma tumour cells. By understanding the mechanism, the research team has opened the way for new therapies to be developed that will provide a viable to alternative to surgery or radiotherapy.

The study, undertaken by researchers from Plymouth University Peninsula Schools of Medicine and Dentistry with colleagues from the State University of New York and Universitat Erlangen-Nurmberg, was led by Professor David Parkinson.

He said: "We have for the first time shown that human schwannoma cells have reduced expression of Sox10 protein and messenger RNA. By identifying this correlation and gaining an understanding of the mechanism of this process, we hope that drug-based therapies may in time be created and introduced that will reduce or negate the need for multiple surgery or radiotherapy."


'/>"/>

Contact: Andrew Gould
andrew.gould@plymouth.ac.uk
44-018-843-8346
University of Plymouth
Source:Eurekalert

Related medicine news :

1. Sugary Sodas, Fruit Punches May Raise Kidney Stone Risk: Study
2. Sunlamps Used to Lowered Blood Pressure in Highly Publicized Dermatology Study
3. Penn medicine study finds broad support for rationing of some types of cancer care
4. Get Fit in Middle Age to Cut Heart Failure Risk, Study Says
5. Young Women Less Healthy Than Men Before Heart Attack: Study
6. Multiple Head Injuries Raise Soldiers Suicide Risk, Study Finds
7. Yoga May Help Ease High Blood Pressure, Study Finds
8. Springer to collaborate with the Italian Society for the Study of Eating Disorders
9. Comorbidities should be factor in prostate biopsy choice, UCI study finds
10. New Study Reveals that Late Night Food Intake Hinders Weight Loss, Making Weight Loss Supplements Like Prescopodene Helpful With Shedding Excess Pounds
11. Novel study reports marijuana users have better blood sugar control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , ... January 23, 2017 , ... ... coffee house-caliber protein and espresso drink, announced its CLICK® Coffee Protein Drink is ... CLICK® Coffee Protein Drink Mix has become popular among health-conscious consumers who love ...
(Date:1/24/2017)... ... January 23, 2017 , ... OSF Ventures, ... the world’s largest start-up platform headquartered in Silicon Valley that connects startups to ... Ventures recently signed a three-year agreement to be a corporate sponsor of Plug ...
(Date:1/24/2017)... , ... January 23, 2017 , ... The January 2017 ... a three-year outcome study on how outdoor behavioral healthcare (OBH) – also known as ... and interpersonal difficulties while experiencing an increased sense of purpose both during and after ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... analyzed statistics from 140 Buzzies users who entered metrics into the product’s app. ... clinical data. The new data showed that within just 30 seconds of using ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... new plugin that allows sleep centers to automatically connect and initialize all their ... thin client browser plugin is quickly installed on first use and then monitors ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... , and GAITHERSBURG, Md. , Jan. ... XON ), a leader in the engineering and industrialization of ... the planet, today announced that it has entered into a ... GNVC ), a clinical-stage company and pioneer in the ... intends to integrate and expand upon GenVec,s expertise in adenoviral ...
(Date:1/24/2017)... PUNE, India , January 24, 2017 ... Research, titled, "Acidity Regulators Market - Global Opportunity Analysis ... regulators was valued at $4,456 million in 2015, and is expected ... 7.96% from 2016 to 2022. Asia-Pacific generated ... lead, followed by North America and ...
(Date:1/24/2017)... SEOUL, Korea , Jan. 24, 2017 ... Reddy,s in New Jersey State court alleging that Dr. ... deficiencies in its Food and Drug Administration (FDA) cGMP ... notes that Dr. Reddy,s repeatedly represented to Mezzion that ... hid its misconduct from Mezzion.  The suit also states ...
Breaking Medicine Technology: